What are the qualifications for pneumonia and Respiratory Syncytial Virus (RSV) vaccination in older adults, young children, and individuals with underlying health conditions such as chronic heart disease, lung disease, or immunocompromised state?

RSV and Pneumonia Vaccination Qualifications

RSV Vaccination Qualifications

Age-Based Recommendations

All adults aged ≥75 years should receive a single lifetime dose of RSV vaccine, regardless of comorbidities or health status. 1, 2

• Adults aged 60-74 years should receive RSV vaccination if they have any chronic medical conditions or risk factors for severe disease 3, 1
• Adults aged 50-59 years with risk factors should receive RSVPreF3 (Arexvy), which is the only vaccine approved for this younger age group 1, 4

High-Risk Medical Conditions (Ages 50-74 Years)

Chronic respiratory conditions:

• Chronic obstructive pulmonary disease (COPD) qualifies for RSV vaccination 3, 1
• Asthma qualifies for RSV vaccination 3, 1
• Bronchiectasis qualifies for RSV vaccination 3, 1
• Interstitial lung disease qualifies for RSV vaccination 3, 1
• Chronic respiratory failure qualifies for RSV vaccination 3, 1

Cardiovascular conditions:

• Chronic heart failure qualifies for RSV vaccination 3, 1
• Coronary artery disease qualifies for RSV vaccination 3, 4
• Other chronic cardiovascular diseases qualify for RSV vaccination 3, 1

Metabolic and endocrine conditions:

• Diabetes mellitus, particularly with complications, qualifies for RSV vaccination 3, 1
• Severe obesity (BMI ≥30 or ≥40 kg/m²) qualifies for RSV vaccination 3, 1

Renal and hepatic conditions:

• Chronic kidney disease, especially end-stage renal disease, qualifies for RSV vaccination 3, 1
• Chronic liver disease qualifies for RSV vaccination 3, 1

Neurological conditions:

• Chronic neurological or neuromuscular diseases qualify for RSV vaccination 3, 1
• Dementia qualifies for RSV vaccination 3, 2

Immunocompromised Status

All immunocompromised adults aged ≥50 years qualify for RSV vaccination, including: 3, 1

• Solid organ transplant recipients 3, 1
• Hematopoietic stem cell transplant recipients 3, 1
• Patients with solid tumors or hematological malignancies 3, 1
• Patients on immunosuppressive medications 3, 1
• HIV-positive individuals 3, 1

Living Situation and Functional Status

• Residents of nursing homes or long-term care facilities qualify for RSV vaccination 3, 1
• Institutionalized individuals qualify for RSV vaccination 3, 1
• Frailty qualifies for RSV vaccination 3, 1

Administration Guidelines

A single lifetime dose is recommended—no booster doses are currently indicated. 1, 2

• The vaccine should preferably be administered between September and November, before or early in the RSV season 3, 1, 2
• RSV vaccine can be co-administered with seasonal influenza vaccine at different injection sites 3, 1, 2
• Patient attestation alone is sufficient evidence of risk factors; extensive medical documentation should not be required 1, 2

Prioritization if Vaccine Supply is Limited

If resources are constrained, prioritize in this order: 1, 4

1. Adults aged ≥75 years
2. Adults aged ≥50 years with multiple comorbidities
3. Residents of long-term care facilities

Important Clinical Considerations

• Previous RSV infection does not confer long-lasting immunity and does not contraindicate vaccination 1, 4
• The burden of RSV in older adults accounts for 10.6% of hospitalizations for pneumonia and 11.4% for COPD exacerbations 1, 5
• RSV infection results in similar hospitalization rates, ICU utilization (15%), and mortality (8%) as influenza A in elderly populations 5
• Immunosenescence (age-related immune decline) significantly increases susceptibility to severe RSV disease, with comorbidities further compounding this risk 1, 6

---

Pneumonia Vaccination Qualifications

Note: The provided evidence focuses primarily on RSV vaccination. For comprehensive pneumococcal vaccination recommendations (PCV15, PCV20, PPSV23), consult current CDC/ACIP guidelines, which typically recommend pneumococcal vaccination for:

• All adults aged ≥65 years
• Adults aged 19-64 years with chronic heart disease, lung disease, diabetes, chronic liver disease, alcoholism, or cigarette smoking
• Adults aged ≥19 years with immunocompromising conditions, including HIV, malignancy, immunosuppressive therapy, solid organ transplant, or functional/anatomic asplenia